NCT07187089

Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

An Open-Label, Single-Arm Study to Assess Growth and Bone Mineral Density in Children ≥6 to <12 Years of Age With Severe Atopic Dermatitis Treated With Dupilumab

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 6 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (also commonly known as eczema). The aim of the study is to see if dupilumab treatment of children with severe atopic dermatitis, which cannot be adequately controlled with topical atopic dermatitis medication, improves growth and bone strength. The study is looking at other research questions, including: • What side effects may happen from taking dupilumab

Conditions

• Severe Atopic Dermatitis (AD)

Interventions

Type	Name	Description
DRUG	dupilumab	Administered per the protocol

Timeline

• Start date: 2025-11-11
• Primary completion: 2027-12-23
• Completion: 2028-01-05
• First posted: 2025-09-22
• Last updated: 2025-11-28

Regulatory

• FDA-regulated drug study